Risk factors
Fortress Biotech (FBIO) risk factors
Item 1A of every Fortress Biotech, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks3 new2 dropped6 reworded
New government policies, tariffs on imports from India, and FDA staffing cuts pose fresh commercialization hurdles for drug products.
Filed Mar 31, 2026 - FY2024 10-K risk factors62 risks
Operating losses reached $110.4 million in 2024 with an accumulated deficit of $740.9 million. Dividends on Series A Preferred Stock were paused in July 2024. Revenue depends heavily on Journey partnership dermatology products.
Filed Mar 31, 2025